Results for
"[search-keyword]"
Sponsor content
45 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEOZA fezolinetant 45 mg film coated tablet blister pack.
-
Australian Public Assessment Report (AusPAR)Veoza (fezolinetant) has been approved for the treatment of moderate to severe hot flashes associated with menopause
-
May-2024Prescription medicine evaluationActive ingredient: avacincaptad pegol.
-
Prescription medicine decision summaryVeoza (fezolinetant) has been approved for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause.
-
Prescription medicine registrationActive ingredients: fezolinetant.
-
Feb-2024Prescription medicine evaluationActive ingredient: enfortumab vedotin.
-
Jan-2024Prescription medicine evaluationActive ingredient: enzalutamide.
-
Dec-2023Prescription medicine evaluationActive ingredient: zolbetuximab.
-
Designation or determinationOrphan Drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PADCEV enfortumab vedotin 30 mg powder for injection vial.